Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 80 and over Aged. Found 155 abstracts

no pagination
Koutrouli N, Anagnostopoulos F, Tsikkinis A, Papastylianou D, Lepore S. Psychometric properties of the Greek version of the Social Constraints Scale in a sample of women with breast cancer. Women Health. 2016 Jan;56(4):413-27.
Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Liu C, Chang P, Freedman GM, Winter KA, Guha C, Abbruzzese JL. RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704. Int J Radiat Oncol Biol Phys. 2016 Mar;94(3):554-60.   PMCID: 4876948
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15;21(16):3610-8.   PMCID: 4790106
Mehrazin R, Uzzo RG, Kutikov A, Ruth K, Tomaszewski JJ, Dulaimi E, Ginzburg S, Abbosh PH, Ito T, Corcoran AT, Chen DY, Smaldone MC, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 2015 Sep;33(9):388e19-388e25.   PMCID: 4289664
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 05;373(19):1803-13.
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood. 2015 Jan 08;125(2):236-41.   PMCID: PMC4287635
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Revenig LM, Canter DJ, Henderson MA, Ogan K, Kooby DA, Maithel SK, Liu Y, Kim S, Master VA. Preoperative quantification of perceptions of surgical frailty. J Surg Res. 2015 Feb;193(2):583-9.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46.
Wang EH, Yu JB, Gross CP, Smaldone MC, Shah ND, Trinh QD, Nguyen PL, Sun M, Han LC, Kim SP. Variation in pelvic lymph node dissection among patients undergoing radical prostatectomy by hospital characteristics and surgical approach: results from the National Cancer Database. J Urol. 2015 Mar;193(3):820-5.
Wang LS, Shaikh T, Handorf EA, Hoffman JP, Cohen SJ, Meyer JE. Dose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Pract Radiat Oncol. 2015 Sep;5(5):e457-63.   PMCID: 4814166
Barr PM, Miller TP, Friedberg JW, Peterson DR, Baran AM, Herr M, Spier CM, Cui H, Roe DJ, Persky DO, Casulo C, Littleton J, Schwartz M, Puvvada S, Landowski TH, Rimsza LM, Dorr RT, Fisher RI, Bernstein SH, Briehl MM. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. Blood. 2014 Aug 21;124(8):1259-65.   PMCID: Pmc4141515
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, Jones MB, Almhanna K, Wenham RM, Sullivan DM, Dalton WS, Gunchenko A, Cheng JD, Siu LL, Gray JE. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 2014 Nov 11;111(10):1932-44.   PMCID: Pmc4229637
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2014 Apr 20;32(12):1210-7.   PMCID: Pmc3986384
Dyer MA, Arvold ND, Chen YH, Pinnell NE, Mitin T, Lee EQ, Hodi FS, Ibrahim N, Weiss SE, Kelly PJ, Floyd SR, Mahadevan A, Alexander BM. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol. 2014 Jun;9:143.   PMCID: 4132230
Hurwitz MD, Ghanouni P, Kanaev SV, Iozeffi D, Gianfelice D, Fennessy FM, Kuten A, Meyer JE, LeBlang SD, Roberts A, Choi J, Larner JM, Napoli A, Turkevich VG, Inbar Y, Tempany CM, Pfeffer RM. Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results. J Natl Cancer Inst. 2014 May;106(5).   PMCID: 4112926
Johnson ME, Zhu F, Li T, Wu H, Galloway TJ, Farma JM, Perlis CS, Turaka A. Absolute lymphocyte count: a potential prognostic factor for Merkel cell carcinoma. J Am Acad Dermatol. 2014 Jun;70(6):1028-35.   PMCID: No NIH funding
Lango MN, Egleston B, Fang C, Burtness B, Galloway T, Liu J, Mehra R, Ebersole B, Moran K, Ridge JA. Baseline health perceptions, dysphagia, and survival in patients with head and neck cancer. Cancer. 2014 Mar 15;120(6):840-7.   PMCID: Pmc3951722
Longacre ML, Ross EA, Fang CY. Caregiving Choice and Emotional Stress Among Cancer Caregivers. Western Journal of Nursing Research. 2014 Jul;36(6):806-24.   PMCID: 4148462
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 80 and over Aged

80 and over Aged Adult Aged Middle Aged Female Male pathology drug therapy mortality therapeutic use adverse effects methods Young Adult Disease-Free Survival Prognosis Kaplan-Meier Estimate analogs & derivatives Neoplasm Staging genetics administration & dosage Antineoplastic Combined Chemotherapy Protocols Monoclonal Antibodies psychology Retrospective Studies Cohort Studies Chemoradiotherapy radiotherapy Antineoplastic Agents Quality of Life complications blood Follow-Up Studies therapy Neoplasms Prospective Studies Taxoids Combined Modality Therapy Prostatic Neoplasms Risk Assessment secondary Survival Analysis Reproducibility of Results Sirolimus chemically induced B-Cell Lymphoma Neoplasm Invasiveness metabolism Neoadjuvant Therapy Local Neoplasm Recurrence Multivariate Analysis Adenocarcinoma Ovarian Neoplasms Skin Neoplasms Biological Tumor Markers Adolescent Survival Proportional Hazards Models Survival Rate Kidney Neoplasms Pancreatic Neoplasms immunology Renal Cell Carcinoma Glioblastoma Genetic Markers ultrasonography quality of health care Psychological Stress Biological Markers skin neoplasm Outcomes Melanoma Rb1 nursing Urothelial carcinoma Socioeconomic Factors Surveys and Questionnaires Age Factors epidemiology Frail Elderly Statistical Factor Analysis Toxicity Ovarian cancer Choice Behavior Genotype surgery head and neck cancer caregiving Veliparib Cisplatin Psychometrics Superoxide Dismutase Lymphocyte count Breast Neoplasms High-Volume Hospitals DNA Repair IGF Type 1 Receptor Fallopian Tube Neoplasms lymph node excision Dose Fractionation Weight Loss Merkel Cell Carcinoma Patient attitudes treatment outcome Oxidative Stress Magnetic Resonance Imaging immune function Social Constraints Scale Dacarbazine Gastrointestinal Diseases Renal cell carcinoma Prostatectomy Piperidines dosage Cross-Sectional Studies Papillary renal cell carcinoma Karnofsky Performance Status Propionates Pain High-Intensity Focused Ultrasound Ablation Randomized Controlled Trials as Topic Intensity-Modulated Radiotherapy etiology biosynthesis Treatment Outcome drug effects Prednisone Radiotherapy Dosage Merkel cell carcinoma Brain Neoplasms Translating Neoplastic Gene Expression Regulation TOR Serine-Threonine Kinases intrusions Phase III Clinical Trials as Topic Double-Blind Method Genetic Polymorphism Urinary Bladder Neoplasms statistics & numerical data Atm Nutritional Status Breast cancer Combination Drug Therapy Deglutition Disorders baseline weight loss Quinazolines Sulfones Fancc Fluorouracil United States Neutropenia
Last updated on Monday, October 03, 2016